US: 1.646.568.9797 (24x5)
UK: 44.330.808.0580 (24x5)
Worldwide: 91.703.051.960 (24x7)
The respiratory therapy area consists of indications that affect the respiratory system in different ways, such as the scarring of lung tissue, and excessive production of mucus in the airways, thereby decreasing lung function. Some of the key indications in this therapy area include asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and idiopathic pulmonary fibrosis (IPF). The causes of respiratory disorders vary significantly across each indication, and include factors such as environment, occupation, genetic predisposition and aging.
In August 2020,Vertex Pharmaceuticals (Ireland) Limited received marketing authorization valid throughout the European Union for Kaftrio which is is a medicine used to treat patients aged 12 years and above who have cystic fibrosis, an inherited disease that has severe effects on the lungs, the digestive system and other organs. Kaftrio is an effective treatment for patients with cystic fibrosis who have two F508del mutations or one F508del and one MF mutation. Two of the active substances in Kaftrio, elexacaftor and tezacaftor, increase the number of CFTR proteins on the cell surface and the other, ivacaftor, improves the activity of the defective CFTR protein. These actions combine to make lung mucus and digestive juices less thick, thereby helping to relieve symptoms of the disease. Both are groups with a high unmet medical need. Patients with one F508del mutation plus other mutations were not covered in the studies, and although the company submitted some data on use in such patients, further data was considered necessary to support authorisation in these groups. In terms of safety, Kaftrio was well tolerated. Therefore, the European Medicines Agency decided that Kaftrio’s benefits are greater than its risks and it can be authorised for use in the EU. The global Breathing Disorders & Treatment market is valued at xx million US$ in 2020 is expected to reach xx million US$ by the end of 2029, growing at a CAGR of xx% during 2021-2029. This report focuses on Breathing Disorders & Treatment volume and value at global level, regional level and company level. From a global perspective, this report represents overall Breathing Disorders & Treatment market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.
The following manufacturers are covered:
- Afferent Pharmaceuticals
- Bristol-Myers Squibb
- Chiesi Farmaceutici
- Dainippon Sumitomo
- Dr. Reddys Laboratories
Segment by Breathing Disorders
- Allergic rhinitis
- Pulmonary hypertension
- Cystic fibrosis
- Idiopathic pulmonary fibrosis
Segment by Route of Dosage
Table of Contents Executive Summary 1 Breathing Disorders & Treatment Market Overview 1.1 Product Overview and Scope of Breathing Disorders & Treatment 1.2 Breathing Disorders & Treatment Segment by Type 1.2.1 Global Breathing Disorders & Treatment Production Growth Rate Comparison by Type (2014-2025) 1.2.2 Asthma 1.2.3 COPD 1.2.4 Allergic rhinitis 1.2.5 Pulmonary hypertension 1.2.6 Cystic fibrosis 1.2.7 Idiopathic pulmonary fibrosis 1.3 Breathing Disorders & Treatment Segment by Application 1.3.1 Breathing Disorders & Treatment Consumption Comparison by Application (2014-2025) 1.3.2 Hospital 1.3.3 Clinics 1.3.4 Other 1.4 Global Breathing Disorders & Treatment Market by Region 1.4.1 Global Breathing Disorders & Treatment Market Size Region 1.4.2 North America Status and Prospect (2014-2025) 1.4.3 Europe Status and Prospect (2014-2025) 1.4.4 China Status and Prospect (2014-2025) 1.4.5 Japan Status and Prospect (2014-2025) 1.5 Global Breathing Disorders & Treatment Market Size 1.5.1 Global Breathing Disorders & Treatment Revenue (2014-2025) 1.5.2 Global Breathing Disorders & Treatment Production (2014-2025) 2 Global Breathing Disorders & Treatment Market Competition by Manufacturers 2.1 Global Breathing Disorders & Treatment Production Market Share by Manufacturers (2014-2019) 2.2 Global Breathing Disorders & Treatment Revenue Share by Manufacturers (2014-2019) 2.3 Global Breathing Disorders & Treatment Average Price by Manufacturers (2014-2019) 2.4 Manufacturers Breathing Disorders & Treatment Production Sites, Area Served, Product Types 2.5 Breathing Disorders & Treatment Market Competitive Situation and Trends 2.5.1 Breathing Disorders & Treatment Market Concentration Rate 2.5.2 Breathing Disorders & Treatment Market Share of Top 3 and Top 5 Manufacturers 2.5.3 Mergers & Acquisitions, Expansion 3 Global Breathing Disorders & Treatment Production Market Share by Regions 3.1 Global Breathing Disorders & Treatment Production Market Share by Regions 3.2 Global Breathing Disorders & ... | read more...